Search results

598 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

In development [GID-TA10457] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

In development [GID-TA10582] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: 31 March 2021

Type

Technology appraisal guidance

Status

In development
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]

In development [GID-TA10756] Expected publication date: 22 September 2021

Type

Technology appraisal guidance

Status

In development
Esketamine for treatment-resistant depression (ID1414)

In development [GID-TA10371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]

In development [GID-TA10305] Expected publication date: 31 March 2021

Type

Technology appraisal guidance

Status

In development
Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: 26 May 2021

Type

Technology appraisal guidance

Status

In development
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

In development [GID-TA10334] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

In development [GID-TA10697] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [ID1602]

In development [GID-TA10524] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]

In development [GID-TA10584] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

In development [GID-TA10766] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

In development [GID-TA10432] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]

In development [GID-TA10674] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care

In development [GID-DT28] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Cutting blocks for total knee arthroplasty

In development [GID-IP1112] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Implantable Vagus Nerve Stimulator in Heart Failure

In development [GID-IP1145] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

In development [GID-IP1151] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Extra corporeal membrane oxygenation for acute heart failure in children

In development [GID-IP1153] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Degradable surgical implant

In development [GID-IP1197] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
MRI guided focussed ultrasound for chronic pain

In development [GID-IP1043] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Ex utero intrapartum therapy for fetal obstruction

In development [GID-IP1156] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Peroral endoscopic myotomy (POEM) for achalasia

In development [GID-IP1229] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

In development [GID-IP1170] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Electrochemotherapy for the treatment of malignant melanoma

In development [GID-IP1041] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

In development [GID-TA10635] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

In development [GID-TA10558] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

In development [GID-TA10667] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Constipation (opioid induced) - lubiprostone [ID646]

In development [GID-TAG367] Expected publication date: 01 October 2014

Type

Technology appraisal guidance

Status

In development
Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 18 August 2021

Type

Technology appraisal guidance

Status

In development
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

In development [GID-TA10402] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

In development [GID-TAG432] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

In development [GID-TAG403] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Obesity - phentermine (with topiramate) [ID543]

In development [GID-TAG439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]

In development [GID-TAG372] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

In development [GID-TAG423] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Prostate cancer - intensity modulated radiotherapy [ID17]

In development [GID-TAG396] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Colon cancer (adjuvant) - irinotecan [ID379]

In development [GID-TAG380] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Head and neck cancer - contusugene ladenovec [ID76]

In development [GID-TAG407] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small cell) - afatinib [ID357]

In development [GID-TAG422] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

In development [GID-TAG330] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Prostate cancer (hormone refractory) - atrasentan [ID390]

In development [GID-TAG379] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development